1025504-45-3

1025504-45-3 structure

Name: Valbenazine
Chemical Name: [(2R,3R,11bR)-9,10-dimethoxy-3-(2-methylpropyl)-2,3,4,6,7,11b-hexahydro-1H-benzo[a]quinolizin-2-yl] (2S)-2-amino-3-methylbutanoate
CAS Number: 1025504-45-3
Molecular Formula: C₂₄H₃₈N₂O₄
Molecular Weight: 418.569
Catalog: Research Areas Neurological Disease
Create Date: 2017-08-01 21:55:37
Modify Date: 2024-01-03 12:21:04
Valbenazine is a prodrug of the (+)-α isomer of tetrabenazine for tardive syndrome therapy, and inhibits VMAT2 function.

Name	[(2R,3R,11bR)-9,10-dimethoxy-3-(2-methylpropyl)-2,3,4,6,7,11b-hexahydro-1H-benzo[a]quinolizin-2-yl] (2S)-2-amino-3-methylbutanoate
Synonyms	Ingrezza (2R,3R,11bR)-3-Isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl L-valinate NBI-98854 L-Valine, (2R,3R,11bR)-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2H-benzo[a]quinolizin-2-yl ester UNII:54K37P50KH (2R,3R,11bR)-9,10-dimethoxy-3-(2-methylpropyl)-1,3,4,6,7,11b-hexahydro-2H-benzo[a]quinolizin-2-yl L-valinate Valbenazine

Description	Valbenazine is a prodrug of the (+)-α isomer of tetrabenazine for tardive syndrome therapy, and inhibits VMAT2 function.
Related Catalog	Signaling Pathways >> Others >> Others Research Areas >> Neurological Disease
In Vivo	Valbenazine shows a distinctive improvement in tardive dyskinesia symptoms during the successful Phase II trial[1].
References	[1]. Müller T, et al. Valbenazine granted breakthrough drug status for treating tardive dyskinesia. Expert Opin Investig Drugs. 2015 Jun;24(6):737-42.